Skip to content

Effectiveness and safety of transdermal cannabis oil (Metta-Osot) to treat knee osteoarthritis patients in Kalasin Province

Effectiveness and safety of transdermal cannabis oil (Metta-Osot) to treat knee osteoarthritis patients in Kalasin Province

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250915006
Enrollment
80
Registered
2025-09-15
Start date
2025-10-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Does transdermal application of cannabis oil (Metta Osot) demonstrate efficacy and safety in alleviating knee pain among patients with osteoarthritis, and if so, in what manner cannabis oil transdermal knee osteoarthritis

Interventions

Cannabis Oil (Metta Osot Formula) Dosage: Start with 2 drops per application and adjust individually to achieve pain relief, not exceeding 4 drops per application. Frequency: Twice daily (morning and
Cannabis oil Metta osot,Coconut oil

Sponsors

Khonkaen University
Lead Sponsor
Department of Thai Traditional and Alternative Medicine
Collaborator

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1 Age 45 to 70 years 2 Able to walk without assistive devices 3 Living in the study area for at least 6 months 4 Able to communicate in Thai listening, speaking, reading, writing 5 Physician diagnosed knee osteoarthritis, WOMAC total score 25 to 45 (moderate OA) 6 Radiographic evidence of Kellgren Lawrence grade 2 knee osteoarthritis 7 Able to understand instructions, follow trial procedures, and comply with study visits 8 Provide accurate information and written informed consent voluntarily

Exclusion criteria

Exclusion criteria: 1Allergy to cannabis or cannabis extracts 2Allergy to coconut oil used as a solvent 3Use of cannabis products or cannabis components within the past 3 months and not discontinued before study participation 4Personal or family history of psychiatric disorders such as schizophrenia, schizoaffective disorder, bipolar disorder, chronic depression, suicidal ideation, or psychosis 5Severe spinal or other leg joint diseases affecting the treated knee Pregnant participants 6Use of anticoagulants such as warfarin, central nervous system depressants such as benzodiazepines, or anticonvulsants such as clobazam 7Presence of wounds on the knee area to be treated

Design outcomes

Primary

MeasureTime frame
Pain score 12 week Visual Analogue Scale

Secondary

MeasureTime frame
An assessment tool used to measure the severity and impact of knee osteoarthritis 12 week WOMAC (Western Ontario and McMaster Universities Osteoarthritis,assess functional mobility and risk of falling 12 week Timed Up and Go Test

Countries

Thailand

Contacts

Public ContactJuthamart Phuneerap

Faculty of Medicine, Khon Kaen University

run_pion@hotmail.com0833278676

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026